| Name | Title | Contact Details |
|---|
Floan-sanders Inc is a East Grand Forks, MN-based company in the Business Services sector.
Harmon & Castella Printing is a Poughkeepsie, NY-based company in the Business Services sector.
As a proven leader delivering an innovative platform to put data first in asset management, Confluence is leading the DataTech evolution. Our vision is to instantaneously transform data into knowledge and deliver it to the world. Beginning with the market downturn and the change in regulatory focus from investor protection to systemic risk, DataTech represents a shift from output-driven to data-driven processes. It represents a strategic mindset that challenges the asset management industry to think about post-trade reporting differently. With DataTech, asset managers and service providers focus on getting the data right first. Then they leverage that same data set across multiple deliverables. The result is greater speed, efficiency and control. The value of DataTech will increase as it evolves. Confluence believes that DataTech will extend beyond RegTech to enable the industry to leverage innovation and data reuse to benefit the entire back-office ecosystem – financial, statutory, performance and investor communications. Headquartered in Pittsburgh, PA, Confluence serves the international fund industry with locations in Ho Chi Minh City, London, and Luxembourg.
Denali Therapeutics is a clinical-stage biopharmaceutical company based in South San Francisco, California. The company focuses on developing therapies for neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, as well as lysosomal storage disorders like Hunter syndrome. Denali employs around 422 professionals and utilizes proprietary blood-brain barrier transport technologies to meet the medical needs of patients with brain-related disorders. Denalis innovative approach includes four engineered transport vehicle systems: Enzyme Transport Vehicle (ETV), Antibody Transport Vehicle (ATV), Protein Transport Vehicle (PTV), and Oligonucleotide Transport Vehicle (OTV). These technologies enable the delivery of various therapeutic agents to the brain. The company collaborates with major pharmaceutical partners, including Sanofi, AbbVie, and Takeda, to enhance the development of its pipeline products, which include DNL310 for Hunter syndrome and DNL151 for Parkinson’s disease. Denalis mission is to advance therapies that address the underlying causes of neurodegeneration, emphasizing a commitment to rigorous science and patient-focused innovation.